High mobility group box 1 inhibition by BoxA attenuates ovalbumin-induced allergic rhinitis in mice

References

• Mattos JL, Woodard CR, Payne SC. Trends in common rhinologic illnesses: analysis of U.S. healthcare surveys 1995–2007. Int Forum Allergy Rhinol. 2011;1(1):3–12.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(2 Suppl):S12–S16.
   PubMed Web of Science ®Google Scholar
• Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the treatment of allergic rhinitis-and eventually nasal polyps? Int Arch Allergy Immunol. 2009;148(2):87–98.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Ohashi Y, Kakinoki Y, et al. Immunotherapy suppresses both Th1 and Th2 responses by allergen stimulation, but suppression of the Th2 response is a more important mechanism related to the clinical efficacy of immunotherapy for perennial allergic rhinitis. Scand J Immunol. 1998;48(2):201–211.
   PubMed Web of Science ®Google Scholar
• Müller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med. 2004;255(3):332–343.
   PubMed Web of Science ®Google Scholar
• Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8(4):195–202.
   PubMed Web of Science ®Google Scholar
• Bellussi LM, Cocca S, Passali GC, et al. HMGB1 in the pathogenesis of nasal inflammatory diseases and its inhibition as new therapeutic approach: a review from the literature. Int Arch Otorhinolaryngol. 2017;21(4):390–398.
   PubMed Web of Science ®Google Scholar
• Salpietro C, Cuppari C, Grasso L, et al. Nasal high-mobility group box-1 protein in children with allergic rhinitis. Int Arch Allergy Immunol. 2013;161(2):116–121.
   PubMed Web of Science ®Google Scholar
• Chen S, Wang Y, Gong G, et al. Ethyl pyruvate attenuates murine allergic rhinitis partly by decreasing high mobility group box 1 release. Exp Biol Med. 2015;240(11):1490–1499.
   Web of Science ®Google Scholar
• Gong G, Xiang L, Yuan L, et al. Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats. PLOS One. 2014;9(3):e89450.
   PubMed Web of Science ®Google Scholar
• Bangert A, Andrassy M, Müller AM, et al. Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc Natl Acad Sci USA. 2016;113(2):E155–E164.
   PubMed Web of Science ®Google Scholar
• Weir HM, Kraulis PJ, Hill CS, et al. Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 1993;12(4):1311–1319.
   PubMed Web of Science ®Google Scholar
• Gong W, Zheng Y, Chao F, et al. The anti-inflammatory activity of HMGB1 a box is enhanced when fused with C-terminal acidic tail. J Biomed Biotechnol. 2010;2010:915234.
   PubMed Web of Science ®Google Scholar
• Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA. 2004;101(1):296–301.
   PubMed Web of Science ®Google Scholar
• Wang FC, Pei JX, Zhu J, et al. Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro. World J Gastroenterol. 2015;21(25):7764–7776.
   PubMed Web of Science ®Google Scholar
• Yang H, Liu H, Zeng Q, et al. Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation. Mol Med. 2019;25(1):13.
   PubMedGoogle Scholar
• Yuan Y, Liu Q, Zhao J, et al. SIRT1 attenuates murine allergic rhinitis by downregulated HMGB 1/TLR4 pathway. Scand J Immunol. 2018;87(6):e12667.
   PubMed Web of Science ®Google Scholar
• Ekanayaka SA, McClellan SA, Peng X, et al. HMGB1 antagonist, box A, reduces TLR4, RAGE, and inflammatory cytokines in the cornea of P. aeruginosa-Infected mice. J Ocul Pharmacol Ther. 2018;34:659–669.
   Web of Science ®Google Scholar
• Yang L, Wang F, Yang L, et al. HMGB1 a-Box reverses brain edema and deterioration of neurological function in a traumatic brain injury mouse model. Cell Physiol Biochem. 2018;46(6):2532–2542.
   PubMedGoogle Scholar
• Fan XH, Cheng L, Yan AH. Ameliorative effect of acetylshikonin on ovalbumin (OVA)-induced allergic rhinitis in mice through the inhibition of Th2 cytokine production and mast cell histamine release. APMIS. 2019;127(10):688–695.
   PubMed Web of Science ®Google Scholar
• Kawauchi H, Yanai K, Wang DY, et al. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci. 2019;20:213.
   PubMed Web of Science ®Google Scholar
• Pawankar R. Inflammatory mechanisms in allergic rhinitis. Curr Opin Allergy Clin Immunol. 2007;7(1):1–4.
   PubMed Web of Science ®Google Scholar
• McKinney K, Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol. 2002;22(19):6797–6808.
   PubMed Web of Science ®Google Scholar
• Agresti A, Lupo R, Bianchi ME, et al. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun. 2003;302(2):421–426.
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–251.
   PubMed Web of Science ®Google Scholar
• Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192(4):565–570.
   PubMed Web of Science ®Google Scholar
• Wang H, Ward MF, Sama AE. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock. 2009;32(4):348–357.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1768–1773.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol. 2005;78(1):1–8.
   PubMed Web of Science ®Google Scholar
• Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. 2008;117(25):3216–3226.
   PubMed Web of Science ®Google Scholar
• Fransson M, Adner M, Erjefält J, et al. Up-regulation of toll-like receptors 2, 3 and 4 in allergic rhinitis. Respir Res. 2005;6:100.
   PubMed Web of Science ®Google Scholar
• Xu H, Shu H, Zhu J, et al. Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF-κB pathway. Exp Ther Med. 2019;18(1):761–768.
   PubMed Web of Science ®Google Scholar
• Wee JH, Zhang YL, Rhee CS, et al. Inhibition of allergic response by intranasal selective NF-κB decoy oligodeoxynucleotides in a murine model of allergic rhinitis. Allergy Asthma Immunol Res. 2017;9(1):61–69.
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Miyata M, Hatsushika K, et al. TGF-beta signaling may play a role in the development of goblet cell hyperplasia in a mouse model of allergic rhinitis. Allergol Int. 2010;59(3):313–319.
   PubMedGoogle Scholar
• Hou C, Kong J, Liang Y, et al. HMGB1 contributes to allergen-induced airway remodeling in a murine model of chronic asthma by modulating airway inflammation and activating lung fibroblasts. Cell Mol Immunol. 2015;12(4):409–423.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103(6):779–788.
   PubMed Web of Science ®Google Scholar